US EditionHigh Point biopharm sees shares soar on FDA news - Business North Carolina
Summary by Business North Carolina
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
High Point biopharm sees shares soar on FDA news - Business North Carolina
Shares for High Point-based vTv Therapeutic soared more than 69% on Monday in early trading after the company announced that the FDA had lifted the clinical hold on its late-stage trial for cadisegliatin, a potential adjunctive oral drug for the treatment of type 1 diabetes. The FDA placed a clinical hold on the trial in July 2024 due to a chromatographic signal in how the drug was absorbed and processed. No patient had been dosed in the trial a…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
